SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

APE fuels culture. Backed by the best club in the world and hundreds of thousands of holders worldwide, it’s the token for digital and IRL communities, builders, creators, collectors, gamers, and beyond.  APE is the native gas token of ApeChain and is available across multiple ecosystems including Ethereum, Arbitrum, Solana and HyperLiquid.z  ApeCoin's mission is is to supercharge its ecosystem by supporting high-quality builders &amp; reinforcing 3 core pillars: ApeChain, Bored Ape Yacht Club, and Otherside.

ApeCoin

ApeCoin is seeing heightened trading volume and speculative momentum as community members discuss a potential breakout and its integration into the broader NFT and gaming ecosystem. While some traders are focused on short-term volatility and technical setups, others are debating its long-term utility and historical price performance.

MaxLinear, Inc. engages in the provision of communications systems-on-chip (SoC) solutions used in broadband, mobile and wireline infrastructure, data center, and industrial and multi-market applications. Its products include cable broadband modems and gateways, wireline connectivity devices, radio frequency transceivers, fiber-optic modules, video set-top boxes and gateways, hybrid analog and digital televisions, direct broadcast satellite outdoor and indoor units, and power management and interface products. The company was founded by Kimihiko Imura, Curtis C. Ling, and Kishore V. Seendripu on September 25, 2003 and is headquartered in Carlsbad, CA.

MaxLinear Inc

MaxLinear is currently trending as investors react to the company's strong Q1 earnings beat and optimistic guidance, which are being driven by a structural shift toward AI-fueled data center infrastructure. The stock has seen massive volume and price volatility as the market reprices the company's role in the optical interconnect supply chain, sparking intense debate among retail traders regarding whether the move is a sustainable re-rating or an overextended momentum squeeze.

Atomera, Inc. engages in the development, commercialization, and licensing of proprietary processes and technologies for the semiconductor industry. It developed Mears Silicon Technology, which increases performance and power efficiency in semiconductor transistors. The company was founded by Robert Mears on November 26, 2001 and is headquartered in Los Gatos, CA.

Atomera Inc

Atomera is trending as investors aggressively trade around significant volume and high short interest, with the community actively speculating that an imminent commercial deal or partnership news is on the horizon. Despite persistent skepticism regarding the lack of recurring revenue, sentiment is currently buoyed by hopeful 'dot-connecting' related to the firm's advanced semiconductor material integration and anticipated industry collaborations.

Harvest Portfolios Group Inc - Harvest Canadian High Income Shares ETF

Harvest Canadian High Income Shares ETF

Investors are closely monitoring the ETF following reports of dividend increases and shifts in underlying portfolio holdings. The community is actively debating the fund's role within broader income-focused portfolios and evaluating its performance relative to other yield-oriented strategies.

VanEck ETF Trust - VanEck Semiconductor ETF

VanEck Semiconductor ETF

VanEck Semiconductor ETF (SMH) is experiencing a parabolic, momentum-driven rally to all-time highs as traders pile into AI infrastructure, despite widespread community debate over whether this represents a sustainable megatrend or an overextended bubble. Investors are closely monitoring record-breaking winning streaks and extreme relative strength indicators, with discussions split between those riding the momentum and others hedging for an inevitable sector rotation or volatility reset.

Intellia Therapeutics, Inc. is a clinical stage genome editing company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course, and creates engineered cells that can treat oncological and immunological diseases. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna, and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.

Intellia Therapeutics Inc

Intellia Therapeutics is trending as investors await a critical Phase 3 data readout for its hereditary angioedema therapy, with high short interest fueling anticipation for a potential short squeeze. The community is actively discussing the stock's significant price volatility and the potential impact of this binary event on the company's long-term position in the gene-editing sector.

Index Coop is a decentralized autonomous organization (DAO) that builds structured DeFi products and strategy tokens. Index Coop offers a suite of sector index products, leverage and inverse products, and yield-generating products. The product suite runs on Set Protocol, an audited, self-custodial DeFi tool that allows for the creation and management of Ethereum-based (or ERC-20) tokens. Changes to the DAO are voted on by the owners of a governance token called INDEX and then implemented by a team of developers. INDEX holders wield voting power on a 1:1 basis, meaning one token equals one vote.

Index Cooperative

Index Cooperative is seeing renewed community interest as traders highlight its low circulating supply and potential for explosive price moves during DeFi market expansions. Supporters are actively discussing the token's governance role, its leverage-focused product suite, and the possibility of a breakout similar to previous cycles.

Chip

CHIP is seeing significant trading volume and social activity following its simultaneous listing on major platforms like Robinhood and Coinbase, fueling an intense community debate between those betting on its long-term AI infrastructure utility and those dismissing it as a short-lived pump-and-dump scheme. Investors are closely monitoring its price consolidation while debating whether the token's early volatility represents a genuine accumulation phase or a coordinated exit by insiders.

Toro Corp. is a shipping company, which engages in the acquisition, owning, chartering, and operation of oceangoing tanker vessels. The firm also provides seaborne transportation services for crude oil and refined petroleum products. It operates through the Aframax/LR2 Tanker and Handysize Tanker segments. The Aframax/LR2 Tanker segment includes vessels operated under time charter contracts, voyage charter contracts, and pools entered into by certain of the subsidiaries. The Handysize Tanker segment consists of vessels operated in a Handysize pool. The company was founded on July 29, 2022 and is headquartered in Limassol, Cyprus.

Toro Corp

Toro Company 

Toro Company is currently trending due to a significant special dividend announcement that has attracted investor interest, alongside community discussions regarding its low float and potential for upward momentum. Many are highlighting the CEO's active participation in open-market share purchases, which is fueling speculation among traders about a possible short-squeeze setup and strong price action.

Amkor Technology, Inc. engages in the provision of outsourced semiconductor packaging and test services. Its services include design, package characterization, test, and wafer bumping services. The company was founded in 1968 and is headquartered in Tempe, AZ.

AMKOR Technology Inc.

Amkor Technology is trending as the community debates its critical role as a semiconductor packaging 'pick-and-shovel' play in the AI supply chain. Investors are closely monitoring the stock's performance amid portfolio rebalancing during high-volatility weeks, weighing its potential for long-term growth against the broader market's rotation into AI infrastructure.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Telomir Pharmaceuticals (NASDAQ:TELO) Shares Down 8.9% - Here's What Happened

Telomir Pharmaceuticals (NASDAQ:TELO) Shares Down 8.9% - Here's What Happened...

<ul><li>According to Telomir, more than 60,000 new cases of Leukemia are diagnosed each year in the U.S.</li><li>Leukemia cells rely heavily on iron as a fuel source, and Telomir-1 in previous research demonstrated the ability to reduce intracellular iron levels.&nbsp;</li><li>The new findings expand on the experimental drug’s previously reported activity in triple-negative breast, pancreatic, and aggressive prostate cancer models.</li></ul>Telomir Pharmaceuticals, Inc. (TELO) said on Friday that its investigational compound Telomir-1 killed aggressive human leukemia (HL60) cells in an in-vitro study.HL60 leukemia cells were treated with Telomir-1, which produced a clear, dose-dependent reduction in viable leukemia cells, indicating strong activity, the company said.Leukemia is a cancer of the blood and bone marrow defined by the uncontrolled growth of abnormal white blood cells.<a href="https://stocktwits.com/symbol/TELO">TELO shares</a> rose 8% at the time of writing.<h2 class="st-heading-2">New Findings</h2>According to Telomir, more than 60,000 new cases of Leukemia are diagnosed each year in the U.S. Leukemia cells rely heavily on iron as a fuel source, and Telomir-1 in previous research demonstrated the ability to reduce intracellular iron levels."The potency observed in HL60 leukemia cells is consistent with the broader biological patterns we have seen throughout Telomir's research…These findings support our scientific framework for evaluating Telomir-1 and inform the ongoing advancement of our overall oncology research program," the company’s chief scientific advisor, Itzchak Angel,<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://telomirpharma.com/#"> said</a>.The new findings expand on the experimental drug’s previously reported activity in triple-negative breast, pancreatic, and aggressive prostate cancer models. The compound is the company’s lead candidate.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around TELO jumped from ‘bearish’ to ‘bullish’ territory over the past 24 hours, while message volume levels rose from ‘extremely low’ to ‘high’ levels.TELO stock is down 66% this year and by 69% over the past 12 months.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/google-ai-infra-chief-must-double-ai-compute-twice-a-year/cLPMFWiREOK">Google AI Infra Chief Says It Must Double AI Compute Twice A Year To Meet Demand: Report</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

In this photo illustration, the Telomir Pharmaceuticals logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

TELO Stock Jumps Pre-market After Early Study Results Show Leukemia Cell Death 

HL60 leukemia cells were treated with Telomir-1, which produced a clear, dose-dependent reduction in viable leukemia cells, indicating strong activity, the company said.

Equity

HL60 leukemia cells were treated with Telomir-1, which produced a clear, dose-dependent reduction in viable leukemia cells, indicating strong activity, the company said.


Shares of Telomir Pharmaceuticals surged nearly 40% in premarket trading on Thursday after the company announced promising new lab results showing that its experimental compound, Telomir-1, can selectively destroy triple-negative breast cancer cells.In laboratory studies using human triple-negative breast cancer (TNBC) cells, researchers observed that as Telomir-1 concentrations increased, more cancer cells stopped growing and eventually died. When iron was reintroduced into the system, the cells regained their ability to survive, pointing to a finding that confirmed Telomir-1’s effects are tied to iron regulation and cellular energy balance.The discovery is significant as TNBC cells are highly dependent on iron to fuel their rapid growth and spread. By cutting off that iron-driven metabolism, Telomir-1 appears to exploit a key vulnerability in these tumors, while normal cells, which process iron differently, remain largely unaffected.Telomir-1 has previously&nbsp;demonstrated the ability to reset abnormal DNA methylation patterns, which are chemical modifications that can alter gene function in preclinical models of cancer and age-related diseases.&nbsp;In this latest study, researchers believe its impact on energy and iron metabolism may stem from its influence on certain enzymes, known as Jumonji domain histone demethylases, which are known to drive tumor aggressiveness and treatment resistance.The study suggests that Telomir-1 may help restore the body’s natural balance, reactivating the normal genetic controls that cancer cells&nbsp;typically shut down to maintain growth.Telomir said it will now seek to use the drug in other hard-to-treat cancers, such as pancreatic and blood cancers, based on these results. The company also expects to soon begin animal studies, a crucial step in the process of seeking FDA approval to begin human trials.On Stocktwits, retail sentiment for Telomir was ‘extremely bullish’ amid ‘extremely high’ message volume.One user said they were surprised the stock hadn’t “gone nuclear” after the breast cancer news broke, adding that they expect it to “go parabolic” in the next session.<stembedurl>https://stocktwits.com/DadiscplinedTrader/message/631612120</stembedurl>Another user commented that the company could eventually attract a buyout offer from a larger pharmaceutical player, suggesting the stock might rise ten to fifteen times, comparing it to past biotech acquisition successes, including that of Provention Bio by Sanofi.<stembedurl>https://stocktwits.com/MarketAttack/message/631581755</stembedurl><a href="https://stocktwits.com/symbol/TELO">Telomir’s stock</a> has declined 60% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Telomir’s stock (TELO) has declined 60% so far in 2025. | Image source: Getty Images

Why Telomir Pharmaceuticals Stock Is Rising 40% Premarket Today

The company said that its experimental drug, Telomir-1, selectively kills aggressive triple-negative breast cancer cells by disrupting their iron-based energy systems.

Shares of Telomir Pharmaceuticals surged during after-hours trading Thursday following the announcement of early laboratory data from research conducted on progeria-affected cells from a young patient.The stock closed at $1.21 on Thursday, then surged 138.8% after hours to $2.89 following the preclinical data.The rare disease, Hutchinson-Gilford Progeria Syndrome (HGPS), emerges from one gene mutation which triggers the accumulation of progerin within the body. The disease affects fewer than 30 children in the U.S.Most start showing symptoms like growth delays and heart problems by age two, and many don’t live past their early teens.&nbsp;The only approved drug, Zokinvy, can add a few years to their lives but doesn’t stop the damage or undo what’s already happened.In the new study, conducted by Smart Assays using cells provided by the Progeria Research Foundation, Telomir-1 improved cell survival in a dose-dependent manner, even under stress conditions.&nbsp;It also reduced levels of reactive oxygen species, a marker of oxidative damage, and corrected iron-induced calcium overload linked to mitochondrial dysfunction.The company stated that these results, observed in actual patient-derived cells, demonstrate that Telomir-1 not only protects cells but also restores critical biological functions.&nbsp;Telomir-1 is designed to regulate metal ions, reduce oxidative stress, restore mitochondrial health, extend telomeres, reverse muscle loss, and reset age-related DNA methylation patterns.CEO Erez Aminov said that the findings support broader potential beyond progeria, including neurodegeneration and metabolic disorders.The results also validated prior preclinical work in animal models, where Telomir-1 extended lifespan and reversed age phenotypes in zebrafish and C. elegans models of Werner syndrome, an adult form of progeria.&nbsp;Telomir is completing IND-enabling studies and is due to meet with the U.S. Food and Drug Administration (FDA) to discuss potential regulatory pathways, including orphan drug designation.On Stocktwits, retail sentiment was ‘extremely bullish’ amid ‘extremely high’ message volume.The Telomir stream on Stocktwits saw a nearly 30% increase in watcher count over the past 24 hours, leading up to late Thursday, with the 24-hour message volume surging up by 8,600%.One user predicted a sharp move, saying Telomir could hit $8–$10 in post-market trading before “a crazy rocket” at the open toward $20 or higher.&nbsp;<stembedurl>https://stocktwits.com/time4themoon/message/621444979</stembedurl>Another user noted the stock’s momentum late in the session, and added that it was “seeing a nice bid going into the extended session close” with expectations to be “jamming in premarket.”<stembedurl>https://stocktwits.com/phijammaslamma/message/621430208</stembedurl><a href="https://stocktwits.com/symbol/TELO">Telomir’s stock</a> has declined 70.3% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Telomir Pharmaceuticals (TELO) said early lab results showed its drug candidate helped restore damaged cells from a child with progeria. (Photo credit: Getty Images)

Telomir Pharma Jumps In After-Hours Trading After Drug Reverses Damage In Progeria Cells; Retail Eyes Bigger Gains

The early lab study used cells from a child with progeria and showed improvements in cell survival, reduced oxidative stress, and restored mitochondrial function, which are key signs of aging. 

Telomir Pharma Jumps In After-Hours Trading After Drug Reverses Damage in Progeria Cells; Retail Eyes Bigger Gains

Telomir Pharmaceuticals, Inc. is a pre-clinical-stage pharmaceutical company, which focuses on the development and commercialization of TELOMIR-1, a novel small molecule being developed to function as an oral in situ therapeutic treatment for human stem cells. The firm’s initial focus on treatments to inhibit the production of pro-inflammatory cytokines, such as IL-17, by oral administration of TELOMIR-1 as a therapeutic treatment for stem cells in situ. TELOMIR-1 is under investigation to provide a potential therapeutic intervention against age-related inflammatory conditions such as hemochromatosis, as well as for post-chemotherapy recovery, by interrupting and preventing the IL-17 induced inflammatory pathways that create the systemic imbalance of cellular metals. The company was founded by Christopher C. Chapman Jr. on August 26, 2021 and is headquartered in Miami, FL.

TELO
Telomir Pharmaceuticals Inc

Feed

News

Sentiment

Fundamentals

Info

Poll

Latest TELO News

TELOTelomir Pharmaceuticals Inc